Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising outcomes in initial human trials . Recent examination indicates https://dftsocial.com/story22456010/retatrutide-emerging-investigations-and-potential-medical-roles